JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Начало・Списък с акции・Kura Oncology Inc

Kura Oncology Inc

Затворен

СекторЗдравеопазване

7.79 5.84

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.77

Максимум

7.87

Ключови измерители
By Trading Economics
Приходи	-8M -74M
Продажби	5.5M 21M
Марж на печалбата	-357.186
Служители	192
EBITDA	-1.3M -74M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+262.45% upside

Дивиденти
By Dow Jones
Следващи печалби	25.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-128M 720M
Предишно отваряне	1.95
Предишно затваряне	7.79

Настроения в новините

By Acuity

78%

22%

324 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

5.575 / 6.6 Подкрепа & съпротива

Kura Oncology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.02.2026 г., 09:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

7.02.2026 г., 09:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.02.2026 г., 05:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

7.02.2026 г., 02:46 ч. UTC

Придобивния, сливания и поглъщания

Big Money, High Anxiety -- Barrons.com

6.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

6.02.2026 г., 21:40 ч. UTC

Придобивния, сливания и поглъщания

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6.02.2026 г., 21:22 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Accelerating in January -- Market Talk

6.02.2026 г., 21:17 ч. UTC

Печалби

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6.02.2026 г., 21:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.02.2026 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6.02.2026 г., 21:13 ч. UTC

Печалби

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6.02.2026 г., 21:13 ч. UTC

Печалби

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6.02.2026 г., 21:04 ч. UTC

Пазарно говорене

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6.02.2026 г., 20:34 ч. UTC

Печалби

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

6.02.2026 г., 20:27 ч. UTC

Печалби

These Stocks Are Today's Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More -- Barrons.com

6.02.2026 г., 20:24 ч. UTC

Пазарно говорене

Oil Futures Settle Higher As U.S.-Iran Talks Get Under Way -- Market Talk

6.02.2026 г., 20:20 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Retreat Ahead of Weekend -- Market Talk

6.02.2026 г., 19:48 ч. UTC

Печалби

Take-Two, Mondelez Get Analyst Attention -- Barrons.com

6.02.2026 г., 19:30 ч. UTC

Придобивния, сливания и поглъщания

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- WSJ

6.02.2026 г., 19:30 ч. UTC

Придобивния, сливания и поглъщания

Justice Department Asking Industry How Netflix or Paramount Deal for Warner Bros. Might Impact Competition, According to Subpoena -- WSJ

6.02.2026 г., 19:30 ч. UTC

Придобивния, сливания и поглъщания

DOJ Asking if Netflix Engaged in 'Exclusionary Conduct' That May Lead to Monopoly, According to Subpoena -- WSJ

6.02.2026 г., 19:17 ч. UTC

Пазарно говорене

USDA Says Farm Income to Decrease in 2026 -- Market Talk

6.02.2026 г., 18:50 ч. UTC

Печалби

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6.02.2026 г., 18:47 ч. UTC

Пазарно говорене

Natural Gas-Infrastructure Operators Take 'Flight to Scale' -- Market Talk

6.02.2026 г., 18:34 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 1 to 412 -- Market Talk

6.02.2026 г., 17:58 ч. UTC

Печалби

Reddit Stock Falls After Strong Earnings. Wall Street Is Debating What's Next. -- Barrons.com

6.02.2026 г., 17:52 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

6.02.2026 г., 17:52 ч. UTC

Пазарно говорене

Печалби

Amazon's CapEx Seen as Misunderstood by Investors -- Market Talk

6.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Kura Oncology Inc Прогноза

Ценова цел

By TipRanks

262.45% нагоре

12-месечна прогноза

Среден 28.38 USD 262.45%

Висок 40 USD

Нисък 16 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Kura Oncology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Kura Oncology Inc през последните 3 месеца.

Техническа оценка

By Trading Central

5.575 / 6.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

324 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.